# CAR-T cell therapy research
**Type:** Topics
**Canonical URL:** https://scholariq.org/topics/car-t-cell-therapy-research/
## Facts
| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on Chimeric Antigen Receptor (CAR) T cell therapy, a form of immunotherapy that uses genetically engineered T cells to target and destroy cancer cells. The papers cover various aspects of CAR T cell therapy, including its application in treating leukemia, lymphoma, and solid tumors, the management of cytokine release syndrome associated with this therapy, and the long-term efficacy and safety of CAR T cell treatment. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t11491 |
| Works | 429 |
## Topic papers all
Showing 15 of 429.
- [Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer](https://scholariq.org/papers/safety-activity-and-immune-correlates-of-anti-pd-1-antibody-in-cancer/)
- [Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer](https://scholariq.org/papers/safety-and-activity-of-anti-pd-l1-antibody-in-patients-with-advanced-cancer/)
- [Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia](https://scholariq.org/papers/tisagenlecleucel-in-children-and-young-adults-with-b-cell-lymphoblastic-leukemia/)
- [Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq](https://scholariq.org/papers/dissecting-the-multicellular-ecosystem-of-metastatic-melanoma-by-single-cell-rna/)
- [LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1](https://scholariq.org/papers/i-lmo2-i-associated-clonal-t-cell-proliferation-in-two-patients-after-gene/)
- [Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade](https://scholariq.org/papers/clonal-neoantigens-elicit-t-cell-immunoreactivity-and-sensitivity-to-immune/)
- [Genomic correlates of response to CTLA-4 blockade in metastatic melanoma](https://scholariq.org/papers/genomic-correlates-of-response-to-ctla-4-blockade-in-metastatic-melanoma/)
- [T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial](https://scholariq.org/papers/t-cells-expressing-cd19-chimeric-antigen-receptors-for-acute-lymphoblastic/)
- [Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates](https://scholariq.org/papers/phase-i-study-of-single-agent-anti-programmed-death-1-mdx-1106-in-refractory/)
- [Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.](https://scholariq.org/papers/rituximab-chimeric-anti-cd20-monoclonal-antibody-therapy-for-relapsed-indolent/)
- [B cells and tertiary lymphoid structures promote immunotherapy response](https://scholariq.org/papers/b-cells-and-tertiary-lymphoid-structures-promote-immunotherapy-response/)
- [Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes](https://scholariq.org/papers/cancer-regression-in-patients-after-transfer-of-genetically-engineered/)
- [Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia](https://scholariq.org/papers/efficacy-and-toxicity-management-of-19-28z-car-t-cell-therapy-in-b-cell-acute/)
- [Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma](https://scholariq.org/papers/idecabtagene-vicleucel-in-relapsed-and-refractory-multiple-myeloma/)
- [PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy](https://scholariq.org/papers/pd-l1-expression-as-a-predictive-biomarker-in-cancer-immunotherapy/)
## Topic primary papers
Showing 15 of 181.
- [Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia](https://scholariq.org/papers/tisagenlecleucel-in-children-and-young-adults-with-b-cell-lymphoblastic-leukemia/)
- [Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq](https://scholariq.org/papers/dissecting-the-multicellular-ecosystem-of-metastatic-melanoma-by-single-cell-rna/)
- [LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1](https://scholariq.org/papers/i-lmo2-i-associated-clonal-t-cell-proliferation-in-two-patients-after-gene/)
- [T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial](https://scholariq.org/papers/t-cells-expressing-cd19-chimeric-antigen-receptors-for-acute-lymphoblastic/)
- [Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes](https://scholariq.org/papers/cancer-regression-in-patients-after-transfer-of-genetically-engineered/)
- [Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia](https://scholariq.org/papers/efficacy-and-toxicity-management-of-19-28z-car-t-cell-therapy-in-b-cell-acute/)
- [Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma](https://scholariq.org/papers/idecabtagene-vicleucel-in-relapsed-and-refractory-multiple-myeloma/)
- [Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy](https://scholariq.org/papers/durable-complete-responses-in-heavily-pretreated-patients-with-metastatic/)
- [Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma](https://scholariq.org/papers/anti-bcma-car-t-cell-therapy-bb2121-in-relapsed-or-refractory-multiple-myeloma/)
- [Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study](https://scholariq.org/papers/ciltacabtagene-autoleucel-a-b-cell-maturation-antigen-directed-chimeric-antigen/)
- [Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma](https://scholariq.org/papers/adoptive-cell-transfer-therapy-following-non-myeloablative-but-lymphodepleting/)
- [Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1](https://scholariq.org/papers/tumor-regression-in-patients-with-metastatic-synovial-cell-sarcoma-and-melanoma/)
- [Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor](https://scholariq.org/papers/chemotherapy-refractory-diffuse-large-b-cell-lymphoma-and-indolent-b-cell/)
- [A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade](https://scholariq.org/papers/a-cancer-cell-program-promotes-t-cell-exclusion-and-resistance-to-checkpoint/)
- [CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy](https://scholariq.org/papers/cd22-targeted-car-t-cells-induce-remission-in-b-all-that-is-naive-or-resistant/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.